Factory supply Bazedoxifene acetate Cas 198481-33-3 with high quality and best price CAS NO.198481-33-3

Professional supplier Bazedoxifene acetate Cas 198481-33-3 with superior quality

Company profile

Wuhan Fortuna Chemical Co.,Ltd established in 2006, is a big integrative chemical enterprise being engaged in Pharmaceutical & its intermediates, Food/Feed additives, Fine chemicals in distributing the products of our own company and affiliated enterprises, are the members of Hubei E-commerce Chamber.

Our company has professional persons who major in chemical R&D and sicentific management, supply fine chemical products with high quality and close service, also supply custom-tailored products according to our clients’ requirement.

We have a positive and self-motivated management work team with a common philosophy, caring and commitment through teamwork, our team strive to achieve success in delighting our clients and ourselves. 

Since Wuhan Fortuna Chemical Co., Ltd founded, we continuously innovate our products and improve our service, sales network. Hence, we initiate the first sale mode on net in China, which is the retail trade of small package bring along wholesale of diversified management modes. Our products are exported widely to South Korea, Vietnam, Australia, Europe and South America, highly recommended by our clients.

We insist on the management creed “Market is our compass, Quality is our life, Credit is our soul”. Clients’ trust is our forward powder, their satisfaction is our struggling goal.

our competitive advantage

Guaranteed purity

High quality & competitive price

Quality control

Fast feedback

Prompt shipment

Bazedoxifene Acetate is a selective estrogen receptor modulator (SERM) used primarily for the prevention and treatment of osteoporosis in postmenopausal women. Below is a structured overview of its key features:

1. Mechanism of Action

• SERM Activity:

  • Agonist in bone: Maintains bone density by mimicking estrogen's protective effects on bone resorption.

  • Antagonist in breast and uterine tissues: Blocks estrogen activity, reducing risks of breast/endometrial cancer.

2. Indications

Osteoporosis Prevention/Treatment: Reduces fracture risk in postmenopausal women.

Combination Therapy: Paired with conjugated estrogens (e.g., Duavee®) to treat moderate-to-severe menopausal vasomotor symptoms (hot flashes) while protecting against osteoporosis.

3. Dosage & Administration

Standard Dose: 20 mg orally once daily (alone or in combination).

Timing: Can be taken with or without food.

Duration: Long-term use under medical supervision.

4. Side Effects

Common: Hot flashes, leg cramps, sweating, gastrointestinal discomfort.

• Serious:

  • Venous Thromboembolism (e.g., DVT, pulmonary embolism).

  • Increased risk of stroke in certain populations.

  • Rare cases of allergic reactions (rash, angioedema).

5. Contraindications

History of venous thromboembolism or active clotting disorders.

Undiagnosed abnormal uterine bleeding.

Pregnancy or breastfeeding (estrogen antagonism may harm fetal development).

Severe hepatic impairment.

6. Drug Interactions

Warfarin: May alter anticoagulant effects (monitor INR).

Cholestyramine: Reduces absorption (separate doses by ≥2 hours).

Strong CYP3A4 Inducers (e.g., rifampin): May decrease efficacy.

7. Advantages Over Other SERMs

Lower risk of endometrial hyperplasia compared to unopposed estrogen therapy.

Combined formulations (e.g., with estrogen) address both menopausal symptoms and bone health.

8. Safety Monitoring

Regular bone density scans (DEXA).

Watch for signs of thrombosis (leg pain, shortness of breath).

Assess liver function in long-term users.

9. Research & Development

Investigated for breast cancer prevention in high-risk postmenopausal women.

Ongoing studies on its role in cardiovascular health (mixed evidence).

Summary

Bazedoxifene acetate offers dual benefits for postmenopausal women by preserving bone density and mitigating estrogen-related risks. Its combination with conjugated estrogens (e.g., Duavee®) uniquely addresses both osteoporosis and vasomotor symptoms. However, thromboembolic risks necessitate careful patient selection and monitoring. It represents a tailored approach to menopausal management, balancing efficacy with safety.